Vidutolimod
Sponsors
Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals
Conditions
Advanced or Metastatic Cancer
Merkel Cell Carcinoma (MCC)
Cutaneous Squamous Cell Carcinoma (CSCC)
Basal Cell Carcinoma (BCC)
Triple Negative Breast Cancer (TNBC)
Non-Small Cell Lung Cancer (NSCLC)Basal Cell CarcinomaCutaneous Squamous Cell CarcinomaLocally Advanced Basal Cell CarcinomaMerkel Cell CarcinomaNon-Small Cell Lung CancerOropharynx Squamous Cell CarcinomaRefractory Melanoma
Phase 2
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
TerminatedNCT04916002
Start: 2021-11-30End: 2024-10-31Updated: 2026-06-09
A Multicenter, Open-label, Phase 2 study of Intratumoral Vidutolimod (CMP-001) in Combination with Intravenous Cemiplimab in Subjects with Selected Types of Advanced or Metastatic Cancer
CompletedCTIS2023-507344-36-01
End: 2024-06-14Target: 26Updated: 2024-01-30
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
Not yet recruitingNCT07808515
Start: 2026-10-15End: 2030-11-13Target: 135Updated: 2026-09-09